# OnCo record classical-vs-basal-like (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/classical-vs-basal-like/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "classical-vs-basal-like" ;
  schema:name "Classical versus basal-like (squamous) subtypes of pancreatic cancer, and GATA6"@en ;
  schema:alternateName "Classical subtype of pancreatic cancer"@en, "Basal-like pancreatic cancer"@en, "Squamous subtype of pancreatic cancer"@en, "Quasimesenchymal subtype"@en, "Moffitt subtypes"@en, "Bailey subtypes"@en, "Collisson subtypes"@en, "GATA6 expression"@en, "GATA6-low"@en, "GATA6-high"@en, "Transcriptional subtypes of PDAC"@en ;
  schema:description "Gene expression divides pancreatic ductal adenocarcinoma into two main types: classical, the commoner, which keeps its pancreatic identity and responds better to chemotherapy, and basal-like or squamous, which has lost it and carries a worse outlook. One gene, GATA6, is high in classical and low in basal-like tumours, so it can stand in for the whole test; it is used in trials, not routine care."@en ;
  schema:url <https://onco.cc/terms/classical-vs-basal-like/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pancreatic_cancer> ;
  schema:citation <https://doi.org/10.1038/nm.2344>, <https://doi.org/10.1038/ng.3398>, <https://doi.org/10.1038/nature16965>, <https://doi.org/10.1158/1078-0432.ccr-17-2994>, <https://doi.org/10.1158/1078-0432.ccr-19-3724>, <https://doi.org/10.1038/s41588-019-0566-9> ;
  onco:tag "gi", "pancreatic" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/kras-wild-type-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/pdac-organoid-pharmacotyping/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/> ;
  onco:pathways <https://onco.cc/pathways/pancreatic-cancer-signalling/>, <https://onco.cc/pathways/emt/> ;
  onco:terms <https://onco.cc/terms/tumour-grade/>, <https://onco.cc/terms/basal-like/>, <https://onco.cc/terms/desmoplasia/> .